

Biocon enters Malaysia Book of Records as largest integrated insulin manufacturing facility

05 August 2022 | News

Commercial operations at the facility commenced in 2016 when Biocon Biologics' recombinant human insulin became the first locally manufactured biosimilar product approved for sale in Malaysia



Biocon Sdn. Bhd., Malaysia, a subsidiary of Biocon Biologics Ltd (BBL), has entered the prestigious Malaysia Book of Records (MBR). The 562,000 sq. ft. facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR, which officially recognizes record-creating and record-breaking achievements in the fields of human endeavour, building & structures, transportation, arts & entertainment, business, sports & games, science & technology, nature etc. in Malaysia.

Biocon Biologics has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The state-of-the-art insulins facility in Johor is the first and only biopharmaceutical sterile injectables facility in Malaysia to receive U.S. Food and Drug Administration (FDA) and European Medicines Agency approvals.

More recently, Biocon's biosimilar insulin Glargine made at Malaysia received a historic U.S. FDA approval as the 'first interchangeable biosimilar'. Through Biocon Sdn Bhd, Biocon Biologics has set up Asia's largest integrated insulin manufacturing and R&D facility in Malaysia at an investment of over \$350 million. This is the largest foreign investment in biotechnology in Malaysia, reflecting Biocon Biologics' commitment to put affordable life-changing insulins within the reach of 2 patients across the world.